Shukra Pharmaceuticals Limited has filed its quarterly compliance certificate with BSE Limited, fulfilling regulatory requirements under SEBI depositories regulations for the quarter ended March 31, 2026.

Regulatory Compliance Filing

The pharmaceutical company submitted the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 on April 8, 2026. The filing was made through the company's Corporate Relationship Department to BSE Limited's General Manager-Listing department.

Registrar and Transfer Agent Confirmation

Purva Sharegistry (India) Private Limited, serving as the company's Registrar and Transfer Agent, issued the confirmation certificate dated April 1, 2026. The certificate confirms compliance with SEBI regulations regarding dematerialisation processes and stock exchange listing requirements.

The registrar confirmed that securities received from depository participants for dematerialisation during the quarter were processed according to prescribed timelines and regulatory guidelines. Ms. Deepali Gaonkar, Compliance Officer at Purva Sharegistry, signed the confirmation certificate.

Dematerialisation Activity

The detailed report for the quarter from January 1, 2026 to March 31, 2026 shows no dematerialisation activity during this period.

Corporate Information

Shukra Pharmaceuticals Limited operates under CIN L24231GJ1993PLC019079, indicating its incorporation in Gujarat in 1993. The company maintains its regulatory compliance through systematic quarterly filings with stock exchanges and depositories as required under SEBI regulations.

Shukra Pharmaceuticals Ltd. conducted its mandatory independent directors meeting on March 16, 2026, fulfilling regulatory requirements under the Securities and Exchange Board of India (LODR) Regulations, 2015, and the Companies Act, 2013.

Meeting Details and Compliance

The meeting was held at the company's registered office and lasted for 30 minutes, commencing at 1:00 PM and concluding at 1:30 PM. This gathering was organized pursuant to Regulation 25(3) of the SEBI (LODR) Regulations, 2015, read with Schedule IV of the Companies Act, 2013, specifically for the Financial Year 2025-26.

Key Agenda Items Reviewed

The independent directors addressed several critical governance matters during their session:

Governance and Performance Assessment

The independent directors conducted a comprehensive evaluation of the company's governance structure. They reviewed the performance of non-independent directors and assessed the overall effectiveness of the board of directors. Additionally, they evaluated the chairperson's performance, taking into account perspectives from both executive and non-executive directors.

Information Flow Evaluation

A significant focus of the meeting was assessing the information flow between the company's management and the board of directors. The independent directors evaluated whether the quality, quantity, and timeliness of information provided enables the board to effectively and reasonably perform their duties.

Regulatory Communication

The outcome of this meeting was formally communicated to BSE Limited's Department of Corporate Services, with the notification signed by Director Ritu Kapoor (DIN: 1033424). This communication ensures compliance with disclosure requirements under Regulation 30 of the SEBI (LODR) Regulations, 2015.